Show simple item record

AuthorHolzer, Thomasdc.contributor.author
Date of accession2016-03-15T06:25:23Zdc.date.accessioned
Available in OPARU since2016-03-15T06:25:23Zdc.date.available
Year of creation2011dc.date.created
AbstractSubstitution of transfused platelet concentrates are often accused to cause HLA-antibody development. Immunization capability of blood products should have been decreased by universal leukoreduction. Aims: This study should re-assess safety of leukocyte depleted blood products with a special focus on HLA-antibody development. Methods:Analysis of outpatient transfusions, patient characteristics, transfused concentrates. HLA-antibody testing was performed at the beginning and end of the observation period by lymphocyte toxicity test and ELISA of HLA-antibodies class I/II. Results: 74 pts were included in this follow up assessment. Patient characteristics: 41 male, 34 female. 18/34 evaluable female pts had pregnancies in patient history. Underlying diseases: hematopoietic disease (n= 61), solid tumours (n= 9) or a combination of both (n= 4). In summary 968 P-PC , 23 A-PC and 110 HLA-matched A-PC were transfused. Median corrected count increment for platelets was 13130 µl. At the first assessment in 23/74 pts reactive results in LCT and/or ELISA for HLA class I or II-antibodies were obtained. LCT was specific positive with HLA-antibody detection in 10/74 patients and unspecific positive in 2/74 patients. ELISA HLA class I was positive with a score > 2 in 17/50 pts (ELISA HLA-class II in 7 pts). Pts with specific or unspecific positive results in LCT and/or ELISA had in median a transfusion history of 2 RBC and 1 PC. In contrast the pts with normal results in LCT and ELISA had a median of 8 RBC and 5 PC transfused. Diagnoses of the pts with specific HLA-antibodies were all hematopoietic. Antibodies class I were associated with insufficient increment. Conclusion: Our data show the prevalence of HLA-antibodies in multi-transfused patients with hematopoietic disease. Our data do not confirm the thesis of a correlation with the number of transfused units. Therefore new strategies for identification of patients with a high individual immunization risk should be discussed.dc.description.abstract
Languagededc.language.iso
PublisherUniversität Ulmdc.publisher
LicenseStandarddc.rights
Link to license texthttps://oparu.uni-ulm.de/xmlui/license_v3dc.rights.uri
KeywordHämotherapiedc.subject
Dewey Decimal GroupDDC 610 / Medicine & healthdc.subject.ddc
MeSHAntigensdc.subject.mesh
MeSHBlood plateletsdc.subject.mesh
MeSHHLA antigensdc.subject.mesh
TitleHuman-Leucocyte-Antigen-Antikörperbildung unter Hämotherapiedc.title
Resource typeDissertationdc.type
DOIhttp://dx.doi.org/10.18725/OPARU-2329dc.identifier.doi
PPN71594701Xdc.identifier.ppn
URNhttp://nbn-resolving.de/urn:nbn:de:bsz:289-vts-79105dc.identifier.urn
GNDAntikörperdc.subject.gnd
GNDBluttransfusiondc.subject.gnd
GNDHLAdc.subject.gnd
GNDThrombozytdc.subject.gnd
FacultyMedizinische Fakultätuulm.affiliationGeneral
Date of activation2012-05-02T13:44:53Zuulm.freischaltungVTS
Peer reviewneinuulm.peerReview
Shelfmark print versionW: W-H 12.857uulm.shelfmark
DCMI TypeTextuulm.typeDCMI
VTS ID7910uulm.vtsID
CategoryPublikationenuulm.category
Bibliographyuulmuulm.bibliographie


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record